Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.
Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.
复制标题
DOI：
10.3389/fmicb.2018.00440
复制
发表时间：
2018
影响因子：
5.2
通讯作者：
Rosini R
中科院分区：
文献类型：
--
作者：
Rojas-Lopez M;Monterio R;Pizza M;Desvaux M;Rosini R
腹泻病是五岁以下儿童死亡的主要原因之一，肠道致病性大肠杆菌（InPEC）是全球这些感染的主要致病菌之一。InPEC对肠道疾病的负担有很大贡献，这是低收入和中等收入国家（亚洲，非洲和拉丁美洲）的一个关键问题。肠道致病型如肠致病性E.大肠杆菌（EPEC）和产肠毒素E.大肠杆菌（ETEC）主要在发展中国家流行，而ETEC菌株是前往这些国家的旅行者腹泻的主要原因。另一方面，肠出血性E.大肠埃希氏菌（EHEC）是世界各地大规模爆发的原因，主要影响发达国家，不仅导致腹泻病，而且导致严重的临床并发症，如出血性结肠炎和溶血性尿毒综合征（HUS）。总体而言，抗生素耐药菌株的出现、卫生保健系统的年度成本增加、旅行者腹泻的高发病率以及HUS发作次数的增加都提高了对有效预防治疗的需求。尽管抗生素的使用在治疗此类感染中仍然很重要，但非抗生素策略要么是限制抗生素耐药菌株增加的关键选择，要么是绝对必要的，例如由EHEC感染引起的疾病，不推荐抗生素治疗。在非抗生素疗法中，疫苗开发是一种选择策略，但迄今为止，还没有针对InPEC感染的有效许可疫苗。几年来，人们一直在努力确定能够减少疟疾负担的有效候选疫苗。本综述的目的是总结针对InPEC的疫苗开发的最新里程碑和见解。
Diarrheal diseases are one of the major causes of mortality among children under five years old and intestinal pathogenic Escherichia coli (InPEC) plays a role as one of the large causative groups of these infections worldwide. InPECs contribute significantly to the burden of intestinal diseases, which are a critical issue in low- and middle-income countries (Asia, Africa and Latin America). Intestinal pathotypes such as enteropathogenic E. coli (EPEC) and enterotoxigenic E. coli (ETEC) are mainly endemic in developing countries, while ETEC strains are the major cause of diarrhea in travelers to these countries. On the other hand, enterohemorrhagic E. coli (EHEC) are the cause of large outbreaks around the world, mainly affecting developed countries and responsible for not only diarrheal disease but also severe clinical complications like hemorrhagic colitis and hemolytic uremic syndrome (HUS). Overall, the emergence of antibiotic resistant strains, the annual cost increase in the health care system, the high incidence of traveler diarrhea and the increased number of HUS episodes have raised the need for effective preventive treatments. Although the use of antibiotics is still important in treating such infections, non-antibiotic strategies are either a crucial option to limit the increase in antibiotic resistant strains or absolutely necessary for diseases such as those caused by EHEC infections, for which antibiotic therapies are not recommended. Among non-antibiotic therapies, vaccine development is a strategy of choice but, to date, there is no effective licensed vaccine against InPEC infections. For several years, there has been a sustained effort to identify efficacious vaccine candidates able to reduce the burden of diarrheal disease. The aim of this review is to summarize recent milestones and insights in vaccine development against InPECs.
登录
查看更多内容
影响因子：
2.8
作者：
Brzuszkiewicz, Elzbieta;Thuermer, Andrea;Schuldes, Joerg;Leimbach, Andreas;Liesegang, Heiko;Meyer, Frauke-Dorothee;Boelter, Juergen;Petersen, Heiko;Gottschalk, Gerhard;Daniel, Rolf
通讯作者：
Daniel, Rolf
影响因子：
5.5
作者：
Cataldi, Angel;Yevsa, Tetyana;Guzman, Carlos A.
通讯作者：
Guzman, Carlos A.
影响因子：
6.4
作者：
Ahmed, A;Li, JP;Szu, SC
通讯作者：
Szu, SC
人类初乳中分泌免疫球蛋白A的检测是针对沙门氏菌，志贺氏菌和肠病毒性大肠杆菌III型分泌系统的蛋白质的粘膜免疫反应。
DOI：
10.1097/inf.0b013e318293306c
发表时间：
2013-10
期刊：
The Pediatric infectious disease journal
影响因子：
--
作者：
Durand D;Ochoa TJ;Bellomo SM;Contreras CA;Bustamante VH;Ruiz J;Cleary TG
通讯作者：
Cleary TG
影响因子：
4.9
作者：
Bitzan, Martin;Poole, Ruth;Riviere, Marc
通讯作者：
Riviere, Marc